Claim · 2026-02-26 · publication · Stated in source · Supported

Generate Biomedicines' prospectus dated 26 February 2026 states an initial public offering of 25,000,000 shares of common stock at $16.00 per share, approved for listing on the Nasdaq Global Select Market under the symbol GENB.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Generate Biomedicines, Inc. IPO prospectus (424B4) → states provision → initial public offering: 25,000,000 shares at $16.00; Nasdaq symbol GENB

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Generate Biomedicines, Inc. IPO prospectus (424B4)states provision ↓initial public offering: 25,000,000 shares at $16.00; Nasdaq symbol GENB

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-generate-ipo-2026
Date: 2026-02-26 · publication Records dated 2026 →

Scope and limitsOffering terms as stated; not evidence of shares sold under the over-allotment option, proceeds realised or the closing.

The evidence 02

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“This is the initial public offering of shares of common stock of Generate Biomedicines, Inc. We are offering 25,000,000 shares of our common stock.”

Location in source Prospectus cover

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (24 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“The initial public offering price per share is $16.00. Our common stock has been approved for listing on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “GENB.”

Location in source Prospectus cover

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (28 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Prospectus date; the prospectus states that the underwriters expect to deliver the shares on or about March 2, 2026.

Record ID aib-co-generate-ipo-2026